NeoGenomics, a leading provider of cancer genetic testing services, is currently facing a patent infringement lawsuit filed by Natera, a rival company in the same field. The lawsuit alleges that NeoGenomics’ RaDaR molecular residual disease (MRD) assay infringes on two of Natera’s patents, which cover aspects of Natera’s Signatera MRD assay.
MRD assays are used to detect the presence of cancer cells after treatment, and are becoming increasingly important in cancer monitoring and management. Both the Signatera and RaDaR assays are considered to be among the most advanced MRD assays available.
Natera filed the lawsuit in July 2023 in the North Carolina Federal District Court. The lawsuit comes on the heels of a recent jury verdict in favor of Natera in a similar patent infringement case against ArcherDX/Invitae Corp.
What are the implications of the lawsuit for NeoGenomics and Natera?
If Natera is successful in its lawsuit, it could have a significant impact on NeoGenomics’ business. The RaDaR assay is one of NeoGenomics’ most important products, and the company could be forced to stop selling it if it is found to be infringing on Natera’s patents.
However, it is also possible that NeoGenomics will be able to successfully defend itself against the lawsuit. NeoGenomics has argued that its RaDaR assay is based on its own proprietary technology and does not infringe on Natera’s patents.
The outcome of the lawsuit is also important for Natera. If Natera is successful, it would further strengthen its position as a leader in the MRD testing market.
What should patients know about the lawsuit?
Patients who are currently using the RaDaR assay should not be concerned about the lawsuit at this time. The lawsuit is still in its early stages, and it is possible that it could take several years to resolve.
However, patients should be aware that the lawsuit could potentially impact their access to the RaDaR assay in the future. If NeoGenomics is found to be infringing on Natera’s patents, the company could be forced to stop selling the assay.
Patients should talk to their doctor about their concerns and discuss alternative MRD testing options, if necessary.
Conclusion
The outcome of the NeoGenomics lawsuit is important for both companies and for patients. If Natera is successful, it could have a significant impact on NeoGenomics’ business and further strengthen Natera’s position as a leader in the MRD testing market. Patients who are currently using the RaDaR assay should talk to their doctor about their concerns and discuss alternative MRD testing options, if necessary.
FAQs
Q: What is MRD testing?
A: MRD testing is used to detect the presence of cancer cells after treatment. MRD testing can be used to monitor patients for recurrence and to assess the effectiveness of cancer treatment.
Q: What are the Signatera and RaDaR MRD assays?
A: The Signatera and RaDaR MRD assays are two of the most advanced MRD assays available. Both assays use circulating tumor DNA (ctDNA) to detect cancer cells. ctDNA is DNA that is released from cancer cells into the bloodstream.
Q: Why is Natera suing NeoGenomics?
A: Natera is suing NeoGenomics because it alleges that NeoGenomics’ RaDaR MRD assay infringes on two of Natera’s patents. Natera’s patents cover aspects of Natera’s Signatera MRD assay.
Q: What are the potential implications of the lawsuit for NeoGenomics and Natera?
A: If Natera is successful in its lawsuit, it could have a significant impact on NeoGenomics’ business. NeoGenomics could be forced to stop selling the RaDaR assay if it is found to be infringing on Natera’s patents. However, it is also possible that NeoGenomics will be able to successfully defend itself against the lawsuit.
If Natera is successful, it would further strengthen its position as a leader in the MRD testing market.
Q: What should patients know about the lawsuit?
A: Patients who are currently using the RaDaR assay should not be concerned about the lawsuit at this time. The lawsuit is still in its early stages, and it is possible that it could take several years to resolve.
However, patients should be aware that the lawsuit could potentially impact their access to the RaDaR assay in the future.